Q-omics provides the consensus-scored ZDHHC15 profile across patient tissues and cancer cell-line models. ZDHHC15 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZDHHC15 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, ZDHHC15 RNA expression shows 21,569 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, and LUAD as cancer lineages where ZDHHC15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC15 survival associations across molecular data types. ZDHHC15 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC15 RNA expression–survival associations across cancer types. High ZDHHC15 expression shows unfavorable associations in BLCA and UCEC, but favorable associations in KIRC, ACC, LUAD and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZDHHC15 RNA expression.
This table summarizes ZDHHC15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZDHHC15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC15 shows lower tumor expression in KIRC, HNSC, KICH, COAD, THCA and LUAD. The KIRC box plot shows higher ZDHHC15 RNA expression in normal versus tumor tissue (log2 FC = −1.438, t-test p < 0.001).
This table shows molecular features associated with ZDHHC15 in patient tissues and cancer cell lines. In patient samples, ZDHHC15 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_SCLC.
